ArticleMetabolic brain disease2024
Therapeutic potential of the extract of giant millipede Telodeinopus Canaliculatus on epileptogenesis and associated anxiety-like behavior.
Article in Metabolic brain disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The secretions of Telodeinopus canaliculatus, a giant millipede, are used in traditional medicine to treat epileptic seizures. Therefore, this work aimed to assess the antiepileptogenic- and anxiolytic-like effects of an extract of T. canaliculatu in mice. Forty-eight mice were divided into six groups of eight each and treated as follows: normal control group received distilled water (10 ml/kg, p.o.); negative control group received received distilled water (10 ml/kg, p.o.); positive control group received sodium valproate (300 mg/kg, p.o.); and test groups received with the extract (30, 50, and 70 mg/kg, p.o.). One hour later, all groups, except the normal control group (distilled water, 10 ml/kg, i.p.), received a daily dose of pentylenetetrazole (25 mg/kg, i.p) until the onset of tonic-clonic seizures on day 24. On day 26 of the experiment, anxious behaviors were assessed. The mice were subsequently sacrificed and brains were collected for neurochemical analyses. The extract (30, 50, 70 mg/kg, p.o.) reduced (p < 0.001) the seizure severity. It also increased the latencies to the onset of seizures. In the elevated plus maze, the extract (50 mg/kg) increased by 51% (p < 0.001) the time spent in the open arms. The extract (50 mg/kg) increased GABA concentration by 28% (p < 0.01) and 37% (p < 0.001) respectively in the hippocampus and amygdala. Moreover, the extract (30 mg/kg) decreased the concentration of malondialdehyde by 47% (p < 0.001) and 42% (p < 0.01) respectively in the same regions. The hydroethanolic extract of T. canaliculatus is endowed with antiepileptogenic and anxiolytic effects.
Indexed as
Identifiers
39673676What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.